Providing a diverse range of perspectives from bullish to bearish, 17 analysts have published ratings on Colgate-Palmolive CL in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 7 | 6 | 1 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 1 | 3 | 2 | 0 | 0 |
| 3M Ago | 2 | 2 | 3 | 1 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $98.41, a high estimate of $112.00, and a low estimate of $83.00. Observing a downward trend, the current average is 4.62% lower than the prior average price target of $103.18.
Exploring Analyst Ratings: An In-Depth Overview
The perception of Colgate-Palmolive by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Korinne Wolfmeyer | Piper Sandler | Lowers | Overweight | $107.00 | $108.00 |
| Lauren Lieberman | Barclays | Raises | Equal-Weight | $89.00 | $83.00 |
| Andrea Teixeira | JP Morgan | Raises | Overweight | $99.00 | $97.00 |
| Andrea Teixeira | JP Morgan | Lowers | Overweight | $97.00 | $103.00 |
| Peter Grom | UBS | Lowers | Buy | $100.00 | $104.00 |
| Mark Astrachan | Stifel | Lowers | Hold | $93.00 | $95.00 |
| Nik Modi | RBC Capital | Lowers | Sector Perform | $98.00 | $101.00 |
| Olivia Tong | Raymond James | Lowers | Outperform | $105.00 | $110.00 |
| Dara Mohsenian | Morgan Stanley | Lowers | Overweight | $104.00 | $111.00 |
| Nik Modi | RBC Capital | Maintains | Sector Perform | $101.00 | $101.00 |
| Mark Astrachan | Stifel | Lowers | Hold | $95.00 | $101.00 |
| Lauren Lieberman | Barclays | Lowers | Equal-Weight | $83.00 | $96.00 |
| Peter Grom | UBS | Lowers | Buy | $104.00 | $112.00 |
| Andrea Teixeira | JP Morgan | Lowers | Overweight | $103.00 | $109.00 |
| Robert Moskow | TD Cowen | Lowers | Buy | $100.00 | $110.00 |
| Chris Carey | Wells Fargo | Lowers | Underweight | $83.00 | $92.00 |
| Korinne Wolfmeyer | Piper Sandler | Lowers | Overweight | $112.00 | $121.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Colgate-Palmolive. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Colgate-Palmolive compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Colgate-Palmolive's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Colgate-Palmolive's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Colgate-Palmolive analyst ratings.
Unveiling the Story Behind Colgate-Palmolive
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
Understanding the Numbers: Colgate-Palmolive's Finances
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Decline in Revenue: Over the 3 months period, Colgate-Palmolive faced challenges, resulting in a decline of approximately -0.1% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Colgate-Palmolive's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.94% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 228.44%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.5%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 40.15, Colgate-Palmolive faces challenges in effectively managing its debt levels, indicating potential financial strain.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
